Abstract: There is provided a bile duct chip that is a bile duct chip (200) including a membrane (210) through which substances are movable from one surface to the other surface, a first substrate (221) having a recessed part that forms a first flow path (220), and a second substrate (231) having a recessed part that forms a second flow path (230), in which the first substrate (221), the membrane (210), the second substrate (231) are stacked in this order, the recessed part of the first substrate (221) has an opening portion facing the one surface of the membrane (210), the recessed part of the second substrate has an opening portion facing the other surface of the membrane (210), the one surface of the membrane (210) forms a part of the first flow path (220), the other surface of the membrane (210) forms a part of the second flow path (230), the first flow path (220) and the second flow path (230) communicate with each other through the membrane (210), and bile duct epithelial cells (222) are disposed on a surface of

Abstract: There are provided a cell aggregate that can be used as a cell preparation in regenerative medicine, maintains the original characteristics of cells, and has high safety, and a method for simply and safely maintaining the cell aggregate size, the cell characteristics and viability suitable for use as a cell preparation in regenerative medicine. According to an aspect of the present invention, a cell aggregate maintaining method is a method including a maintenance process of maintaining a liquid containing a plurality of the cell aggregates at a temperature which is lower than a culture temperature of the cells and at which the liquid is not frozen.

Abstract: A method of producing a mesodermal-lineage primitive streak cell includes a first step of culturing pluripotent stem cells in a medium containing FGF2, BMP (bone morphogenetic protein) 4, a GSK-3? inhibitor, and retinoic acid or a derivative thereof and a second step of culturing cells obtained in the first step in a medium containing FGF2, a GSK-3? inhibitor, and BMP7.

Abstract: A medium for culturing and expanding nephron progenitor cells, the medium containing a GSK-3? inhibitor, a ROCK inhibitor, and at least one fibroblast growth factor selected from the group consisting of FGF9 and FGF20. Also, a method for culturing and expanding nephron progenitor cells using the medium. Also, a method for producing renal organoids, the method including a step of culturing and expanding nephron progenitor cells using the above method for culturing and expanding nephron progenitor cells, and a step of differentiating the cultured and expanded nephron progenitor cells into renal organoids.

Abstract: A method of producing renal progenitor cells from pluripotent stem cells involves culturing pluripotent stem cells in a medium containing FGF2, BMP4, a GSK-3? inhibitor, and retinoic acid or a derivative thereof, culturing the resulting cells in a medium containing FGF2, a GSK-3? inhibitor, and BMP7, culturing the resulting cells in a medium containing FGF2, a GSK-3? inhibitor, BMP7, and a TGF? inhibitor, culturing the resulting cells in a medium containing FGF2, a GSK-3? inhibitor, BMP7, activin, and a ROCK (Rho-kinase) inhibitor, culturing the resulting cells in a medium containing retinoic acid or a derivative thereof, and FGF9, and culturing the resulting cells in a medium containing a GSK-3? inhibitor and FGF9, to induce renal progenitor cells from intermediate mesodermal cells.

Abstract: A method for acquiring and producing high-purity renal progenitor cells from a renal progenitor cell population into which pluripotent stem cells are induced to differentiate, by identifying a cell surface antigen marker specific to renal progenitor cells. The high-purity renal progenitor cells can be used in regenerative medicine for renal diseases, such as renal failure.

Abstract: Provided is a method for isolating a ureteric bud tip cell from cells, a tissue, or an organoid comprising the ureteric bud tip cell, comprising the following steps of contacting the cells, tissue, or organoid comprising the ureteric bud tip cell with a very low density lipoprotein receptor (VLDL-R) binding agent, and isolating the ureteric bud tip cell using the binding agent as an indicator.

Abstract: The present invention provides: a method for producing renal progenitor cells from intermediate mesoderm cells, which comprises a step of culturing intermediate mesoderm cells in a medium containing a TGF? signaling activator(s) and a BMP inhibitor(s); the renal progenitor cells produced by the method; a pharmaceutical composition comprising the renal progenitor cells; and a therapeutic drug for kidney diseases comprising the renal progenitor cells.

Abstract: A method for concentrating renal progenitor cells involves extracting MET-positive cells and/or AGTR2-positive cells from a renal progenitor cell-containing cell population. The MET-positive cells and/or AGTR2-positive cells are extracted using an anti-MET antibody and/or an anti-AGTR2 antibody. The renal progenitor cell-containing cell population is obtained from pluripotent stem cells. The renal progenitor cells are OSR1 (odd-skipped related 1)-positive and SIX2 (SIX Homeobox 2)-positive.

Abstract: This invention provides a method for stably producing alveolar epithelial progenitor cells from pluripotent stem cells, including steps of culturing pluripotent stem cells in (1) a medium containing activin A and a GSK3? inhibitor, (2) a medium containing a BMP inhibitor and a TGF? inhibitor, and (3) a medium containing BMP4, retinoic acid, and a GSK3? inhibitor.

Abstract: This invention provides a method for stably producing alveolar epithelial progenitor cells from pluripotent stem cells, including steps of culturing pluripotent stem cells in (1) a medium containing activin A and a GSK3? inhibitor, (2) a medium containing a BMP inhibitor and a TGF? inhibitor, and (3) a medium containing BMP4, retinoic acid, and a GSK3? inhibitor.

Abstract: An object of the present application is to provide a method for inducing the differentiation from pluripotent stem cells, particularly iPS cells and ES cells, into ureteric bud cells. Another object of the present application is to provide a system for producing ureteric bud-like tissue from pluripotent stem cells through each stage of differentiations, i.e. anterior primitive streak cells, anterior intermediate mesoderm cells and Wolffian duct cells. Yet another object of the present application is to provide a method for maintaining ureteric bud-like organoids. Another object of the present application is to provide a method for expansion-culturing ureteric bud-like tip tissue.

Abstract: A method for acquiring and producing high-purity renal progenitor cells from a renal progenitor cell population into which pluripotent stem cells are induced to differentiate, by identifying a cell surface antigen marker specific to renal progenitor cells. The disclosed method may include, for example, the steps of: (i) culturing the pluripotent stem cells under conditions that induce differentiation into renal progenitor cells; and (ii) sorting a cell population from the cells obtained at step (i), by using at least one cell surface marker selected from the group consisting of CD9(?), CD55(?), CD106(+), CD140a(+), CD140b(+), CD165(+), CD271(+) and CD326(?).

Abstract: A method of producing renal progenitor cells from pluripotent stem cells involves culturing pluripotent stem cells in a medium containing FGF2, BMP4, a GSK-3? inhibitor, and retinoic acid or a derivative thereof, culturing the resulting cells in a medium containing FGF2, a GSK-3? inhibitor, and BMP7, culturing the resulting cells in a medium containing FGF2, a GSK-3? inhibitor, BMP7, and a TGF? inhibitor, culturing the resulting cells in a medium containing FGF2, a GSK-3? inhibitor, BMP7, activin, and a ROCK (Rho-kinase) inhibitor, culturing the resulting cells in a medium containing retinoic acid or a derivative thereof, and FGF9, and culturing the resulting cells in a medium containing a GSK-3? inhibitor and FGF9, to induce renal progenitor cells from intermediate mesodermal cells.

Abstract: A method for acquiring and producing high-purity renal progenitor cells from a renal progenitor cell population into which pluripotent stem cells are induced to differentiate, by identifying a cell surface antigen marker specific to renal progenitor cells. The disclosed method may include, for example, the steps of: (i) culturing the pluripotent stem cells under conditions that induce differentiation into renal progenitor cells; and (ii) sorting a cell population from the cells obtained at step (i), by using at least one cell surface marker selected from the group consisting of CD9(?), CD55(?), CD106(+), CD140a(+), CD140b(+), CD165(+), CD271(+) and CD326(?).

Abstract: A method for producing hepatocytes from hepatoblasts is provided. The method includes the step of culturing the hepatoblasts in a medium containing a compound selected from the group consisting of pregnenolone and an adrenergic agonist. The hepatoblasts can be obtained by culturing endodermal cells in a medium containing DMSO, and the endodermal cells can be obtained by culturing pluripotent stem cells in a medium containing Activin A and a GSK-3? inhibitor. Accordingly, a method for producing hepatocytes from pluripotent stem cells is also provided by employing the method of the present invention.

Abstract: Provided is a method for generating pancreatic bud cells, having the step of culturing PDX1+/NKX6.1+ cells in a medium containing KGF, EGF and a BMP inhibitor. The culturing step may be performed in suspension cultures or in adherent cultures. When the cells are cultured in adherent cultures, the cells may be cultured in a medium further containing a ROCK inhibitor or a nonmuscie myosin II inhibitor.

Abstract: Provided are: a method for producing biliary epithelial progenitor cells, said method comprising a step for culturing hepatoblasts in a medium containing TGF? and EGF; and a method for constructing a three-dimensional duct-like structure of biliary epithelial progenitor cells, said method comprising a step for culturing hepatoblasts or biliary epithelial progenitor cells in a medium containing HGF, EGF, a Notch inhibitor and a GSK3 inhibitor in the presence of a three-dimensional scaffold material.

Abstract: The present invention relates to a method for producing pancreatic progenitor cells from pluripotent stem cells. More specifically, the present invention relates to a method for producing pancreatic progenitor cells, comprising causing the action of a factor having the inhibitory activity for cyclin-dependent kinase 8 and/or cyclin-dependent kinase 19 (hereinafter, also abbreviated to CDK8/19).

Abstract: Provided is a method for generating pancreatic bud cells, having the step of culturing PDX1+/NKX6.1? cells in a medium containing KGF, EGF and a BMP inhibitor. The culturing step may be performed in suspension cultures or in adherent cultures. When the cells are cultured in adherent cultures, the cells may be cultured in a medium further containing a ROCK inhibitor or a nonmuscle myosin II inhibitor.